Milrinone

Milrinone is a phosphodiesterase inhibitor, a cardiotonic drug with positive inotropic and vasodilating effects, which can be used to treat acute or chronic refractory congestive heart failure.

Millinone is a cardiotropic drug, belonging to phosphodiesterase inhibitors. By inhibiting phosphodiesterase, the drug can increase the concentration of cyclic adenosine phosphate and calcium in cardiomyocytes, thereby effectively strengthening myocardial contractility and increasing cardiac output, so as to exert positive muscle strength. In addition, Milrinone can also play a vasodilator role by directly acting on the small arteries.

milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

当社は、緊密な協力関係にある多くの高品質の工場を有しており、高品質の製品と競争力のある価格を提供できます。また、大量購入には割引も提供できます。また、当社は多くの専門の貨物運送会社と協力し、製品を安全かつスムーズにお客様の手元に届けることができます。納期は、支払い確認後約3〜20日です。

Milrinone is a PDE3 (phosphodiesterase 3) inhibitor that exhibits vasodilator and positive inotropic effects. Milrinone's positive inotropic activity can be inhibited by carbachol (sc-202092). Research indicates that Milrinone can increase platelets and enhance cAMP levels. Milrinone is an inhibitor of PDE3A and PDE3B.
Milrinone, commonly known and marketed as the drug Primacor, is a medication used in patients suffering from heart failure. Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility. Milrinone also works to vasodilate vessels which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. Milrinone has been used in those suffering from heart failure for many years.

1. 貴社は工場ですか、それとも貿易会社ですか?
当社は産業と貿易を統合し、ワンストップサービスを提供する会社です。OEMも受け付けております。

2. サンプルは提供されますか? 無料ですか、それとも追加料金がかかりますか?
サンプルは無料です。サンプルの送料はお客様負担となります。

3. 品質管理に関する証明書はありますか?
品質を保証する ISO 9001:2008 認証。

4. 見積もりを取得するには、何を提供すればよいですか?
必要な製品タイプ、注文数量、住所、具体的な要件をお知らせください。参考用に見積書をすぐに作成いたします。

5. どのような支払い方法をご希望ですか? どのような条件が受け入れられますか?
受け入れられる配送条件: FOB、CFR、CIF、EXW。
受け入れられる支払い通貨：USD;
受け入れられる支払いタイプ: T/T、Western Union、Paypal、Trade Assurance。
使用言語：英語。